Related references
Note: Only part of the references are listed.Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab First-in-Human Healthy Volunteer Trial
Christine Voors-Pette et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Inhibition of platelet GPVI induces intratumor hemorrhage and increases efficacy of chemotherapy in mice
Julia Volz et al.
BLOOD (2019)
Functional significance of the platelet immune receptors GPVI and CLEC-2
Julie Rayes et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
The contribution of platelet glycoprotein receptors to inflammatory bleeding prevention is stimulus and organ dependent
Julie Rayes et al.
HAEMATOLOGICA (2018)
The contribution of platelet glycoprotein receptors to inflammatory bleeding prevention is stimulus and organ dependent
Julie Rayes et al.
HAEMATOLOGICA (2018)
Platelets and vascular integrity: how platelets prevent bleeding in inflammation
Benoit Ho-Tin-Noe et al.
BLOOD (2018)
Platelet glycoprotein VI aids in local immunity during pneumonia-derived sepsis caused by gram-negative bacteria
Theodora A. M. Claushuis et al.
BLOOD (2018)
Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks
Kristell Lebozec et al.
MABS (2017)
Single platelets seal neutrophil-induced vascular breaches via GPVI during immune-complex-mediated inflammation in mice
Angele Gros et al.
BLOOD (2015)
Blocking neutrophil diapedesis prevents hemorrhage during thrombocytopenia
Carina Hillgruber et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes
Ilaria Maestrini et al.
NEUROLOGY (2015)
Efficacy and Safety of Platelet Glycoprotein Receptor Blockade in Aged and Comorbid Mice With Acute Experimental Stroke
Peter Kraft et al.
STROKE (2015)
Targeting Glycoprotein VI and the Immunoreceptor Tyrosine-Based Activation Motif Signaling Pathway
David Stegner et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Pathology of human plaque vulnerability: Mechanisms and consequences of intraplaque haemorrhages
Jean-Baptiste Michel et al.
ATHEROSCLEROSIS (2014)
New advances in treating thrombotic diseases: GPVI as a platelet drug target
Peng Jiang et al.
DRUG DISCOVERY TODAY (2014)
Platelet ITAM signaling is critical for vascular integrity in inflammation
Yacine Boulaftali et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Platelet GPVI: a target for antithrombotic therapy?!
Sebastian Duetting et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
A Humanized Glycoprotein VI (GPVI) Mouse Model to Assess the Antithrombotic Efficacies of Anti-GPVI Agents
Pierre Henri Mangin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Targeting platelets in acute experimental stroke - Impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding
Christoph Kleinschnitz et al.
CIRCULATION (2007)
Human platelet glycoprotein VI function is antagonized by monoclonal anti body-derived Fab fragments
C Lecut et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
Glycoprotein VI but not α2β1 integrin is essential for platelet interaction with collagen
B Nieswandt et al.
EMBO JOURNAL (2001)